Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure.

Caltabiano S, Cizman B, Burns O, Mahar KM, Johnson BM, Ramanjineyulu B, Serbest G, Cobitz AR.

Clin Kidney J. 2019 Feb 18;12(5):693-701. doi: 10.1093/ckj/sfz013. eCollection 2019 Oct.

2.

Cardiovascular Event Rates Among Hemodialysis Patients Across Geographical Regions-A Snapshot From The Dialysis Outcomes and Practice Patterns Study (DOPPS).

Stirnadel-Farrant HA, Karaboyas A, Cizman B, Bieber BA, Kler L, Jones D, Cobitz AR, Robinson BM.

Kidney Int Rep. 2019 Mar 28;4(6):864-872. doi: 10.1016/j.ekir.2019.03.016. eCollection 2019 Jun.

3.

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis.

Meadowcroft AM, Cizman B, Holdstock L, Biswas N, Johnson BM, Jones D, Nossuli AK, Lepore JJ, Aarup M, Cobitz AR.

Clin Kidney J. 2019 Feb;12(1):139-148. doi: 10.1093/ckj/sfy014. Epub 2018 Mar 19.

4.

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease.

Holdstock L, Cizman B, Meadowcroft AM, Biswas N, Johnson BM, Jones D, Kim SG, Zeig S, Lepore JJ, Cobitz AR.

Clin Kidney J. 2019 Feb;12(1):129-138. doi: 10.1093/ckj/sfy013. Epub 2018 Mar 9.

5.

An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects.

Cizman B, Sykes AP, Paul G, Zeig S, Cobitz AR.

Kidney Int Rep. 2018 Mar 3;3(4):841-850. doi: 10.1016/j.ekir.2018.02.009. eCollection 2018 Jul.

6.

Anemia and mortality in patients with nondialysis-dependent chronic kidney disease.

Stirnadel-Farrant HA, Luo J, Kler L, Cizman B, Jones D, Brunelli SM, Cobitz AR.

BMC Nephrol. 2018 Jun 11;19(1):135. doi: 10.1186/s12882-018-0925-2.

7.

The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects.

Caltabiano S, Mahar KM, Lister K, Tenero D, Ravindranath R, Cizman B, Cobitz AR.

Pharmacol Res Perspect. 2018 Mar 9;6(2):e00327. doi: 10.1002/prp2.327. eCollection 2018 Apr.

8.

The occurrence of increased intraperitoneal volume events in automated peritoneal dialysis in the US: role of programming, patient/user actions and ultrafiltration.

Cižman B, Lindo S, Bilionis B, Davis I, Brown A, Miller J, Phillips G, Kriukov A, Sloand JA.

Perit Dial Int. 2014 Jun;34(4):434-42. doi: 10.3747/pdi.2013.01157.

9.
10.

Relationship between drain volume/fill volume ratio and clinical outcomes associated with overfill complaints in peritoneal dialysis patients.

Davis ID, Cizman B, Mundt K, Wu L, Childers R, Mell R, Prichard S.

Perit Dial Int. 2011 Mar-Apr;31(2):148-53. doi: 10.3747/pdi.2010.00012. Epub 2011 Jan 31. Review.

PMID:
21282375
11.

The costs and benefits of automatic estimated glomerular filtration rate reporting.

den Hartog JR, Reese PP, Cizman B, Feldman HI.

Clin J Am Soc Nephrol. 2009 Feb;4(2):419-27. doi: 10.2215/CJN.04080808. Epub 2009 Jan 28.

12.

Association of donor inflammation- and apoptosis-related genotypes and delayed allograft function after kidney transplantation.

Israni AK, Li N, Cizman BB, Snyder J, Abrams J, Joffe M, Rebbeck T, Feldman HI.

Am J Kidney Dis. 2008 Aug;52(2):331-9. doi: 10.1053/j.ajkd.2008.05.006.

13.

Combination embolization and radiofrequency ablation therapy for renal cell carcinoma in the setting of coexisting arterial disease.

Mondshine RT, Owens S, Mondschein JI, Cizman B, Stavropoulos SW, Clark TW.

J Vasc Interv Radiol. 2008 Apr;19(4):616-20. doi: 10.1016/j.jvir.2007.12.444.

PMID:
18375310
14.

Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease?

Brukamp K, Doyle AM, Bloom RD, Bunin N, Tomaszewski JE, Cizman B.

Clin J Am Soc Nephrol. 2006 Jul;1(4):685-94. Epub 2006 Mar 15. Review.

15.

Administration of parenteral iron and mortality among hemodialysis patients.

Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G.

J Am Soc Nephrol. 2004 Jun;15(6):1623-32.

16.

The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods.

Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S148-53.

17.

Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.

Cizman B.

Nephrol Dial Transplant. 2003 Jul;18 Suppl 5:v47-9. Review.

PMID:
12817070
18.

Pseudohyperphosphatemia in a hyperphosphatemic hemodialysis patient.

Suchin EJ, Cizman B, Connolly BR, DiBattista WJ, Agus ZS.

Am J Kidney Dis. 2002 Nov;40(5):E18.

PMID:
12407666
19.

Intrathymic kidney cells delay the onset of lupus nephritis in MRL-lpr/lpr mice.

Bloom RD, O'Connor T, Cizman B, Kalluri R, Naji A, Madaio MP.

Int Immunol. 2002 Aug;14(8):867-71.

PMID:
12147623
20.

Treating hypertension in the patient who has had a stroke.

Cizman B, Townsend RR.

J Clin Hypertens (Greenwich). 2002 Mar-Apr;4(2):135. No abstract available.

21.

Sarcoidosis: association with human leukocyte antigen class II amino acid epitopes and interaction with environmental exposures.

Rossman M, Thompson B, Frederick M, Cizman B, Magira E, Monos D.

Chest. 2002 Mar;121(3 Suppl):14S. No abstract available.

PMID:
11893656
22.

Arterial hypertension and renal allograft survival.

Mange KC, Cizman B, Joffe M, Feldman HI.

JAMA. 2000 Feb 2;283(5):633-8.

PMID:
10665703
23.
24.

Language guiding therapy: the case of dehydration versus volume depletion.

Mange K, Matsuura D, Cizman B, Soto H, Ziyadeh FN, Goldfarb S, Neilson EG.

Ann Intern Med. 1997 Nov 1;127(9):848-53. Review.

PMID:
9382413
25.

New DRB1*1120 allele; another example of the transition between the DR11 and DR13 families of alleles.

Cizman BB, Kearns DJ, McKeen ME, Heron SD, Wu J, Griffith BB, Argyris EG, Kamoun M, Zmijewski CM, Williams TM, Monos DS.

Tissue Antigens. 1996 Jul;48(1):52-4. No abstract available.

PMID:
8864175
26.

Arginine at positions 13 or 70-71 in pocket 4 of HLA-DRB1 alleles is associated with susceptibility to tuberculoid leprosy.

Zerva L, Cizman B, Mehra NK, Alahari SK, Murali R, Zmijewski CM, Kamoun M, Monos DS.

J Exp Med. 1996 Mar 1;183(3):829-36.

27.

Identification of DRB1 allele (DRB1*1316) with aspartate at position 86: evolutionary considerations and functional implications.

Cizman BB, Heron SD, McKeen ME, Kearns DJ, Bassinger S, Griffith BB, Argyris EG, Kamoun M, Zmijewski CM, Williams TM, Monos DS.

Tissue Antigens. 1996 Feb;47(2):153-4. No abstract available.

PMID:
8851732
28.

Genetic polymorphism of the human tumor necrosis factor region in insulin-dependent diabetes mellitus. Linkage disequilibrium of TNFab microsatellite alleles with HLA haplotypes.

Monos DS, Kamoun M, Udalova IA, Csanky E, Cizman B, Turetskaya RL, Smirnova JB, Zharkov VG, Gasser D, Zmijewski CM, et al.

Hum Immunol. 1995 Oct;44(2):70-9.

PMID:
8847231
29.

Identification of HLA-DRB1(*)1114 by oligonucleotide typing and DNA sequencing.

Heron SD, McKeen ME, Cizman BB, Kearns DJ, Argyris EG, Wu J, Griffith BB, Kamoun M, Zmijewski CM, Bunin N, et al.

Immunogenetics. 1995;42(5):436-7. No abstract available.

PMID:
7590984
30.

Hantavirus disease as a cause for hematuria and acute tubular necrosis?

Cizman B.

Am J Kidney Dis. 1994 Oct;24(4):730-1. No abstract available.

PMID:
7942834
31.

DNA-based HLA typing of nonhematopoietic tissue used to select the marrow transplant donor for successful treatment of transfusion-associated graft-versus-host disease.

Friedman DF, Kwittken P, Cizman B, Argyris E, Kearns J, Yang SY, Zmijewski C, Bunin N, Douglas SD, Monos D.

Clin Diagn Lab Immunol. 1994 Sep;1(5):590-6.

32.

A subgroup of murine monoclonal anti-deoxyribonucleic acid antibodies traverse the cytoplasm and enter the nucleus in a time-and temperature- dependent manner.

Yanase K, Smith RM, Cĭzman B, Foster MH, Peachey LD, Jarett L, Madaio MP.

Lab Invest. 1994 Jul;71(1):52-60.

PMID:
8041118
33.

Identification of a new HLA-DPB1 allele (DPB1*5101) by oligotyping and nucleotide sequencing.

Argyris EG, Gibson CF, Cizman B, Kamoun M, Zmijewski CM, Williams TM, Monos DS.

Immunogenetics. 1994;40(2):164. No abstract available.

PMID:
8026866
34.

Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins.

Foster MH, Cizman B, Madaio MP.

Lab Invest. 1993 Nov;69(5):494-507. Review. No abstract available.

PMID:
8246442
35.

[Kidney transplantation in the treatment of patients with end-stage renal failure].

Cizman B, Malovrh M, Kandus A, Drinovec J.

Acta Chir Iugosl. 1990;37 Suppl 1:113-8. Slovenian.

PMID:
2327193
36.

Evidence for Hantavirus disease in Slovenia, Yugoslavia.

Avsic-Zupanc T, Cizman B, Gligić A, Hoofd G, van der Groen G.

Acta Virol. 1989 Aug;33(4):327-37.

PMID:
2574939
37.

Renal involvement in Hantavirus disease.

Cizman B, Ferluga D, Kaplan-Pavlovcic S, Koselj M, Drinovec J, Avsic T.

Adv Exp Med Biol. 1989;252:173-80. No abstract available.

PMID:
2571242
38.

The value of needle renal allograft biopsy.

Malovrh M, Drinovec J, Kandus A, Bren A, Cizman B, Ferluga D, Rott T.

Transplant Proc. 1988 Aug;20(4):597-8. No abstract available.

PMID:
3043809
39.

Follow-up of donors in living related renal transplantation.

Drinovec J, Malovrh M, Kandus A, Cizman B, Luzar S, Kosak M, Ravnik L, Kveder R, Ponikvar R, Mocivnik M, et al.

Transplant Proc. 1987 Oct;19(5):3645-6. No abstract available.

PMID:
3313878

Supplemental Content

Loading ...
Support Center